Zobrazeno 1 - 10
of 175
pro vyhledávání: '"Alfons A. den Broeder"'
Autor:
Iris Rose Peeters, Alfons A. den Broeder, William J Taylor, Nathan den Broeder, Marcel Flendrie, Noortje van Herwaarden
Publikováno v:
Trials, Vol 24, Iss 1, Pp 1-16 (2023)
Abstract Background Long-term gout treatment is based on reducing serum urate levels using urate-lowering therapy (ULT). Most guidelines recommend using a lifelong continuation treat-to-target (T2T) strategy, in which ULT is dosed or combined until a
Externí odkaz:
https://doaj.org/article/5f9b64ad6e8340238360ec1fcc8063b3
Autor:
Thomas E. Bolhuis, Diane Marsman, Frank H. J. van den Hoogen, Alfons A. den Broeder, Nathan den Broeder, Aatke van der Maas
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-8 (2022)
Abstract Background To develop and assess a prediction model for polymyalgia rheumatica (PMR) relapse within the first year of glucocorticoid (GC) treatment. Methods A retrospective PMR cohort (clinical diagnosis) from a rheumatology department was u
Externí odkaz:
https://doaj.org/article/d175a1689d354123a4d926104e990ace
Autor:
Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 5, Pp 2680-2684 (2022)
Background Biologics for psoriasis are registered in standard dosages. In patients with low disease activity, reduction of the dose by interval prolongation can prevent overtreatment, and lower risks and costs. However, fear for increased anti-drug a
Externí odkaz:
https://doaj.org/article/536a53e9789542ddb193b8939be0e2cc
Autor:
Marianne A. Messelink, Matthijs S. van der Leeuw, Alfons A. den Broeder, Janneke Tekstra, Marlies C. van der Goes, Marloes W. Heijstek, Floris Lafeber, Paco M. J. Welsing
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-12 (2022)
Abstract Background Biological disease-modifying anti-rheumatic drugs (bDMARDs) are effective in the treatment of rheumatoid arthritis (RA) but are expensive and increase the risk of infection. Therefore, in patients with a stable low level of diseas
Externí odkaz:
https://doaj.org/article/ae6474191a04470b878ca215137fdecc
Autor:
Frouwke Veenstra, Lise M. Verhoef, Merel Opdam, Alfons A. den Broeder, Wing-Yee Kwok, Inger L. Meek, Cornelia H. M. van den Ende, Marcel Flendrie, Noortje van Herwaarden
Publikováno v:
BMC Rheumatology, Vol 6, Iss 1, Pp 1-6 (2022)
Abstract Objective Gout and diabetes mellitus type 2 (DM) frequently co-exist. The pharmacological effects of metformin may include anti-inflammatory and urate lowering effects. The objective of this study was to test these effects in patients with g
Externí odkaz:
https://doaj.org/article/cbf6b93851664781b72edd639b1649ec
Autor:
Diane E. Marsman, Thomas E. Bolhuis, Nathan den Broeder, Alfons A. den Broeder, Aatke van der Maas
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-14 (2022)
Abstract Background Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people older than 50, resulting in pain and stiffness of the neck, shoulder, and pelvic girdle. To date, glucocorticoids (GC) remain the cornerstone of tr
Externí odkaz:
https://doaj.org/article/28cc67cbe5864bfe95fa1ee833b6cf8c
Autor:
Matthijs S. van der Leeuw, Marianne A. Messelink, Janneke Tekstra, Ojay Medina, Jaap M. van Laar, Saskia Haitjema, Floris Lafeber, Josien J. Veris-van Dieren, Marlies C. van der Goes, Alfons A. den Broeder, Paco M. J. Welsing
Publikováno v:
Arthritis Research & Therapy, Vol 24, Iss 1, Pp 1-11 (2022)
Abstract Background Biological disease-modifying antirheumatic drugs (bDMARDs) are effective in the treatment of rheumatoid arthritis. However, as bDMARDs may also lead to adverse events and are expensive, tapering them is of great clinical interest.
Externí odkaz:
https://doaj.org/article/b92d4cd330bb41329143ebcf30cce34d
Autor:
Céleste J.T. van der Togt, Lise M. Verhoef, Bart J.F. van den Bemt, Nathan den Broeder, Rob ter Heine, Alfons A. den Broeder
Publikováno v:
Therapeutic Advances in Musculoskeletal Disease, Vol 14 (2022)
Background: Tofacitinib is a Janus Kinase (JAK) inhibitor used for the treatment of rheumatoid arthritis (RA) and psoriatic arthritis (PsA), dosed as 5 mg twice daily (BID). It is primarily metabolized by the cytochrome P-3A (CYP3A) enzyme, and there
Externí odkaz:
https://doaj.org/article/a1142d7178994bf980659960cd087b8a
Publikováno v:
Frontiers in Neurology, Vol 13 (2022)
Externí odkaz:
https://doaj.org/article/4345db12727a4cab976c32956a17b123
Autor:
Maike H. M. Wientjes, Sadaf Atiqi, Gerrit Jan Wolbink, Michael T. Nurmohamed, Maarten Boers, Theo Rispens, Annick de Vries, Ronald F. van Vollenhoven, Bart J. F. van den Bemt, Alfons A. den Broeder
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-9 (2021)
Abstract Background A substantial proportion of rheumatoid arthritis (RA) patients discontinues treatment with tumour necrosis factor inhibitors (TNFi) due to inefficacy or intolerance. After the failure of treatment with a TNFi, treatment can be swi
Externí odkaz:
https://doaj.org/article/469fd6c7ea734e45953465a9681f5bdb